Ignacio Dei-Cas; Florencia Giliberto; Alberto Penas Steinhardt

Authors

Ignacio Dei-Cas Presidente Perón Hospital, Avellaneda, Buenos Aires, Argentina
Florencia Giliberto National Council for Scientific and Technical Research, Autonomous City of Buenos Aires, Argentina
Alberto Penas Steinhardt National University of Lujan, Buenos Aires, Argentina

Keywords:

psoriasis, gut microbiota, metagenomics

Abstract

Introducción: La psoriasis es una enfermedad inflamatoria crónica inmunomediada. La psoriasis tipo 1 (Ps1) o psoriasis de inicio temprano es la forma más frecuente de psoriasis y presenta una fuerte base genética. La microbiota intestinal está implicada en la maduración del sistema inmunitario y en múltiples vías metabólicas. Los trastornos en la composición bacteriana intestinal o disbiosis conllevan importantes consecuencias funcionales y han sido implicados en múltiples enfermedades.

Author Biographies

Ignacio Dei-Cas, Presidente Perón Hospital, Avellaneda, Buenos Aires, Argentina

Dermatologist doctor

Florencia Giliberto, National Council for Scientific and Technical Research, Autonomous City of Buenos Aires, Argentina

Doctor in Biochemistry, Laboratory of Dystrophinopathies, Faculty of Pharmacy and Biochemistry, University of Buenos Aires

Alberto Penas Steinhardt, National University of Lujan, Buenos Aires, Argentina

Doctor in Biology, Computational Genomics Laboratory, Department of Basic Sciences

References

I. Griffiths CEM, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271.

II. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386:983-994.

III. Lønnberg AS, Skov L, Duffy DL, Skytthe A, et ál. Genetic factors explain variation in the age at onset of psoriasis: a population-based twin study. Acta Derm Venereol. 2016;96:35-38.

IV. Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450-456.

V. Wiśniewski A, Matusiak Ł, Szczerkowska-Dobosz A, Nowak I, et ál. The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset. Hum Immunol. 2018;79:109-116.

VI. Singh S, Pradhan D, Puri P, Ramesh V, et ál. Genomic alterations driving psoriasis pathogenesis. Gene. 2019;683:61-71.

VII. Huttenhower C, Gevers D, Knight R, Abubucker S, et ál. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-214.

VIII. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front. Microbiol. 2018;9:1459.

IX. Takeshita J, Grewal S, Langan SM, Mehta NN, et ál. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76:377-390.

X. Ramírez-Boscá A, Navarro-López V, Martínez-Andrés A, Such J, et ál. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151:670-671.

XI. Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55:379-390.

XII. Zákostelská Z, Málková J, Klimešová K, Rossman P, et ál. Intestinal microbiota promotes psoriasis-like skin inflammation by enhancing Th17 response. PLoS One. 2016;11:e0159539.

XIII. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164:337-340.

XIV. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, et ál. The human microbiome project. Nature. 2007;449:804-810.

XV. Blaut M. Composition and Function of the Gut Microbiome. The Gut Microbiome in Health and Disease. 2018:5-30.

XVI. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, et ál. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-484.

XVII. Li D, Wang P, Wang P, Hu X, et ál. The gut microbiota: A treasure for human health. Biotechnol Adv. 2016;34:1210-1224.

XVIII. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17:219-232.

XIX. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14:573-584.

XX. Maruvada P, Leone V, Kaplan LM, Chang EB. The human microbiome and obesity: moving beyond associations. Cell Host Microbe. 2017;22:589-599.

XXI. Patterson E, Ryan PM, Cryan JF, Dinan TG, et ál. Gut microbiota, obesity and diabetes. Postgrad Med J. 2016;92:286-300.

XXII. Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, et ál. The gut microbiome in human neurological disease: A review. Ann Neurol. 2017;81:369-382.

XXIII. Song H, Yoo Y, Hwang J, Na Y-C, et ál. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016;137:852-860.

XXIV. Saha A, Robertson ES. Microbiome and Human Malignancies. En Robertson E. (eds) Microbiome and Cancer. Current Cancer Research. Humana Press, Cham. 2019: 1-22.

XXV. Codoñer FM, Ramírez-Bosca A, Climent E, Carrión-Gutierrez M, et ál. Gut microbial composition in patients with psoriasis. Sci Rep. 2018;8:3812.

XXVI. Huang L, Gao R, Yu N, Zhu Y, et ál. Dysbiosis of gut microbiota was closely associated with psoriasis. Sci China Life Sci. 2019;62:807-815.

XXVII. Shapiro J, Cohen NA, Shalev V, Uzan A, et ál. Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls. J Dermatol. 2019;46:595-603.

XXVIII. Tan L, Zhao S, Zhu W, Wu L, et ál. The Akkermansia muciniphila is a gut microbiota signature in psoriasis. Exp Dermatol. 2018;27:144-149.

XXIX. Scher JU, Ubeda C, Artacho A, Attur M, et ál. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67:128-139.

XXX. Hidalgo‐Cantabrana C, Gómez J, Delgado S, Requena López S, et ál. Gut microbiota dysbiosis in a cohort of patients with psoriasis. Br J Dermatol. 2019;181:1287-1295.

XXXI. Chen YJ, Ho HJ, Tseng CH, Lai ZL, et ál. Intestinal microbiota profiling and predicted metabolic dysregulation in psoriasis patients. Exp Dermatol. 2018;27:1336-1343.

XXXII. Goodrich JK, Waters JL, Poole AC, Sutter JL, et ál. Human genetics shape the gut microbiome. Cell. 2014;159:789-799.

XXXIII. Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS. 2016;30:2737-2751.

XXXIV. Bach Knudsen KE, Lærke HN, Hedemann MS, Nielsen TS, et ál. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients. 2018;10:1499.

XXXV. Zhou L, Zhang M, Wang YT, Dorfman RG, et ál. Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis. 2018;24:1926-1940.

XXXVI. Eppinga H, Sperna Weiland CJ, Bing Thio H, van der Woude CJ, et ál. Similar depletion of protective faecalibacterium prausnitziiin psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016;10:1067-1075.

XXXVII. Kosiewicz MM, Dryden GW, Chhabra A, Alard P. Relationship between gut microbiota and development of T cell associated disease. FEBS Lett. 2014;588:4195-4206.